Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South Korea
Su‐Hyun Kim(National Cancer Center), Ho Jin Kim(National Cancer Center), Seung Ho Choo(Samsung Medical Center), Jeong Bin Bong(Chosun University Hospital), Ha Young Shin(Yonsei University), Tai‐Seung Nam(Chonnam National University Hospital), Jin Myoung Seok(Samsung Medical Center), Ohyun Kwon(Eulji University), Jong Seok Bae(Hallym University), Sooyoung Kim(Ulsan College), Eun Hee Sohn(Chungnam National University), Sa‐Yoon Kang(Jeju National University), Yoo Hwan Kim(Hallym University Sacred Heart Hospital), Yeon Hak Chung(Samsung Medical Center), Seong‐il Oh(Kyung Hee University), Byeol‐A Yoon(Kyungpook National University Hospital), Sukyoon Lee(Inje University Busan Paik Hospital), Jae‐Won Hyun(Seoul National University Hospital), Young‐Min Lim(Ulsan College), You‐Ri Kang(National Cancer Center), Sohyeon Kim(Ulsan College), Young Nam Kwon(Yonsei University), Eun‐Jae Lee(Ulsan College), Hung Youl Seok(Keimyung University), Sun‐Young Kim(Hanyang Cyber University), Sung‐Min Kim(Seoul National University Hospital), Nam‐Hee Kim(Korea National Institute of Health), Suk-Won Ahn(Chung-Ang University Hospital), Jong-Kuk Kim(Dong-A University), Sun‐Young Oh(Inje University Busan Paik Hospital), Min Su Park(Yeungnam University College), Ki Hoon Kim(Inje University Sanggye Paik Hospital), Woohee Ju(Chung-Ang University Hospital), Eun Bin Cho(Changwon National University), Ju‐Hong Min(Samsung Medical Center), Kyong Jin Shin(Inje University Haeundae Paik Hospital)
Cited by 11
Related Papers
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
|Journal of Neuroinflammation|2018|740
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
|The Lancet|2019|722
Neuromyelitis optica
|Nature Reviews Disease Primers|2020|464
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder
|Multiple Sclerosis Journal|2011|284